RxSight Inc(RXST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.14 | Insider Own | 7.24% | Shs Outstand | 41.6M | Perf Week | - |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | -23.42% | Insider Trans | -0.56% | Shs Float | 38.6M | Perf Month | 2.73% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.31 | Inst Own | 103.49% | Short Float | 10.68% | Perf Quarter | -19.41% |
| Income | -0.05B | P/S | 1.6 | EPS this Y | 0.66% | Inst Trans | 6.62% | Short Ratio | 5.21 | Perf Half Y | -28.05% |
| Sales | 0.13B | P/B | 0.77 | EPS next 5Y | 10.81% | ROA | -14.19% | Short Interest | 4.12M | Perf YTD | -52.98% |
| Book/sh | 6.33 | P/C | 0.98 | EPS past 3/5Y | 26.63% - | ROE | -17.35% | 52W High | -62.93% ($13.22) | Perf Year | -44.38% |
| Cash/sh | 5.02 | P/FCF | - | Sales past 3/5Y | 40% 55.74% | ROIC | -17.24% | 52W Low | 11.36% ($4.40) | Perf 3Y | -76.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -42.62% | Gross Margin | 77.5% | Volatility(W/M) | 3.77% 4.97% | Perf 5Y | -59.54% |
| Dividend TTM | - | EV/Sales | 0.04 | Sales Y/Y TTM | -13.24% | Oper. Margin | -43.2% | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.61 | EPS Q/Q | -0.8% | Profit Margin | -36.8% | RSI (14) | 47.3 | Recom | 3.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.07 | Sales Q/Q | 0.31% | SMA20 | 2.63% ($4.77) | Beta | 1.21 | Target Price | $7.57 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/11/3 | SMA50 | -9.93% ($5.44) | Rel Volume | 1 | Prev Close | $4.9 |
| Employees | 461 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 11.96% 3.66% | SMA200 | -23.61% ($6.41) | Avg Volume(3M) | 0.79M | Price | $4.9 |
| IPO | 2021/7/30 | Option/Short | Yes/Yes | Trades | 4598 | Volume | 787,700 | Change | - |
👁️ RxSight is a US medical device company specializing in adjustable intraocular lenses (IOLs) for cataract surgery. Its flagship product, the Light Adjustable Lens, allows the lens power to be fine-tuned after surgery through UV light treatments, offering personalized vision correction that sets it apart from conventional fixed lenses. The company has been strengthening its position in the ophthalmic medical device market with its proprietary technology.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Next earnings report: November 3
5 days to go.
RXST has a sound balance sheet but weak earning power
Of every $100 in sales, $43.20 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +0.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $160. Peers typically go for $154. Compared with its own 2-year average, it is 276% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -59.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #77 of 142 in the industry
Based on market cap of $204M.
ELMD#75 Electromed Inc $226M PER 21.0 
PROF#76 Profound Medical Corp $211M PER - RXST#77 RxSight Inc $204M PER - 
INGN#78 Inogen Inc $192M PER - 
MXCT#79 MaxCyte Inc $176M PER - 
FAQ
What kind of company is RXST?
RXST belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of RXST?
The market cap of RXST is approximately $204M, ranking 4,012 within its sector.
What is the 52-week high and low for RXST?
RXST has recorded a 52-week high of $13.22 and a low of $4.40.
